Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous methylprednisolone for complicated or fulminant acute myocarditis
2023-504169-22-02Phase 3Authorised
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, single-blind trial in acute myocarditis comparing High-dose intravenous methylprednisolone with Placebo / control (2 arms). Primary endpoint: Primary composite endpoint. Planned start Jul 2024; status: authorised.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
acute myocarditis
Beyond the preview
Go deeper on 2023-504169-22-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504169-22-02.